ISEMBYLD® Infusion Therapy

ISEMBYLD® has no boxed warning, and the labeled warnings and precautions section contains exactly one item. It is worth reading carefully, because it is the single safety issue that shapes care on this therapy.

ISEMBYLD® may increase the risk of fractures, including serious fractures. In the pivotal trial, fractures occurred in 9% of patients treated at the recommended 10 mg/kg dose compared with 2% on placebo. Femur fractures occurred in three treated patients. In an ongoing open-label extension at twice the recommended dose, fractures occurred in 9% of patients, including five serious femur fractures. No patient stopped treatment because of a fracture.

Most patients who fractured already had low bone density, previous fractures, or contractures, all of which are common in SMA. Some fractures happened without a clear precipitating event such as a fall. Animal studies also showed adverse effects on bone, particularly at the hip.

What this means in practice

• ISEMBYLD® is used with caution in patients with a history of low bone density or multiple fractures. That history does not rule treatment out, but it should be on the chart before the first dose.
• Report any new pain in a limb, hip, or back, any refusal to bear weight, any new reluctance to be moved or transferred, and any unexplained swelling or bruising. In a patient who cannot easily describe where it hurts, a change in behavior around handling may be the first sign.
• Do not assume a fracture requires a fall. Several occurred without one.
• If a fracture does occur, your prescriber weighs the risks and benefits of continuing. There is no automatic stop and no dose reduction step, since 10 mg/kg is the only recommended dose.

Bone health care that is already part of SMA management, including vitamin D and calcium, safe handling and transfer technique, and monitoring of bone density, becomes more important on this therapy rather than less.

The most common side effects, reported in 20% or more of patients treated at 10 mg/kg and more often than with placebo, were:

• Upper respiratory tract infections, including nasopharyngitis, sinusitis, nasal congestion, and runny nose (66%, compared with 54% on placebo)
• Vomiting (30%) and gastroenteritis (23%)
• Cough (28%) and sore throat (21%)
• Other viral infections, including COVID-19, RSV, and influenza (26%)
• Headache (23%)
• Hypersensitivity reactions, mostly skin findings such as rash, eczema, hives, or flushing (21%)

Also reported in 5% or more of treated patients and more often than placebo: diarrhea (17%), infusion and injection site reactions (13%), abdominal pain (13%), joint pain (13%), bruising (11%), falls (11%), fractures (9%), fatigue (9%), pain in an arm or leg (9%), hematoma (6%), and muscle pain (6%).

The respiratory items deserve context

Respiratory infections top this list, and they were also common in the placebo group, because weakened breathing and cough muscles make them common in SMA generally. The difference matters anyway. Serious events of pneumonia occurred in three treated patients and none on placebo, and acute respiratory failure in the setting of a lower respiratory infection occurred in two treated patients and one on placebo. A chest infection in a patient with SMA is not a minor illness. Report fever, a change in cough, increased secretions, more work to breathe, or any change in ventilator or cough-assist needs early rather than waiting it out.

A lab change you may hear about

Creatine phosphokinase, a muscle enzyme, rose in 28% of treated patients compared with 12% on placebo, with 6% exceeding two and a half times the upper limit of normal. Patients with these elevations were generally without symptoms. A raised CPK in a patient on a drug that acts on muscle is not unexpected, but it is worth knowing about in advance so that an incidental result ordered elsewhere does not cause alarm.

Call your care team right away if you experience:

• New pain in an arm, leg, hip, or the back, new unwillingness to be moved or transferred, or unexplained swelling or bruising over a bone
• Fever, worsening cough, increased secretions, or any increase in breathing effort or support needs
• Rash, hives, swelling of the face, lips, or tongue, wheezing, or trouble breathing during or after an infusion
• Vomiting or diarrhea that will not settle, particularly in a smaller child where dehydration comes on quickly

ISEMBYLD® has no boxed warning and no contraindications. There is no screening protocol to clear before the first dose, no premedication, no restricted distribution program, and no required observation period. By the standards of most therapies described on this site, the barrier to starting is low. The things to watch for come later, and they are bone and breathing rather than immune suppression.

Pregnancy and reproductive potential

This is the part of the label that needs the most attention, and it reads differently from the contraception windows on other pages. Based on animal data, ISEMBYLD® may cause fetal harm. Like other monoclonal antibodies it crosses the placenta, with greater fetal exposure in the third trimester. In rats given the drug through pregnancy and nursing, offspring showed delayed sexual maturation and altered neurobehavioral responses at all doses tested, and male offspring showed impaired reproductive function at the highest dose. No dose without these effects was identified.

Animal data also suggest that apitegromab-mstn may affect male and female reproductive function following exposure during postnatal development or in adulthood. In juvenile rats dosed through the equivalent of childhood and adolescence, female reproductive measures were reduced in adulthood, again with no dose free of the effect. The label does not set a specific contraception window, which means this is a conversation to have with your prescriber rather than a rule to follow. Given that most patients starting this therapy are children, it is a conversation that should happen with families early and be revisited as a patient grows, not raised for the first time in adolescence.

Tell your care team right away if you become pregnant during treatment. There are no data on apitegromab-mstn in human milk, and breastfeeding decisions are made case by case.

Use in specific populations

• Children: established from 2 years of age. Not established below 2.
• Older adults: no patients aged 65 or over were studied, so the response in that group is unknown.
• Kidney or liver impairment: no dose adjustment is expected. The antibody is broken down into peptides and amino acids rather than cleared by the kidneys or metabolized by the liver.
• Drug interactions: none expected, and neither nusinersen nor risdiplam affects how ISEMBYLD® behaves in the body.

Anti-drug antibodies

Over 52 weeks, 1 of 128 treated patients (0.8%) tested positive for antibodies against the drug at a single time point, and no neutralizing antibodies were found. That is among the lowest rates of any biologic described on this site.

Before you start, tell your care team if you

• Have a history of low bone density, osteoporosis, or previous fractures
• Have had scoliosis surgery, hip instability, or significant contractures
• Use noninvasive ventilation, cough assist, or other respiratory support, or have had repeated chest infections
• Are pregnant, planning a pregnancy, or breastfeeding
• Have stopped, paused, or changed your SMN2-targeted therapy, since ISEMBYLD® is approved only alongside it

Keep the Medication Guide, and do not stop treatment without speaking to your prescriber first.

ISEMBYLD® referrals are more straightforward than most, since there is no screening panel to clear and no enrollment program to complete. Two items decide eligibility on their own: confirmed 5q SMA and documented current SMN2-targeted therapy. A complete referral should include:

• Confirmed diagnosis of 5q SMA, with genetic testing documenting SMN1 status and, where available, SMN2 copy number
• Current SMN2-targeted treatment, naming nusinersen or risdiplam, with start date, current dose, and the next scheduled dose. This is the item that most often stalls a referral, and a prescription record alone is not enough
• Any prior gene therapy with onasemnogene abeparvovec, with the date given
• Date of birth and current weight with the date it was measured, plus a plan for recalculating the dose as a growing child gains weight
• Ambulatory status and current motor function, with a baseline HFMSE or equivalent score and the date, since response is assessed against it
• Bone health history: prior fractures with sites and dates, any bone density testing, vitamin D status, and current calcium or vitamin D supplementation
• Orthopedic history including scoliosis and any spinal fusion, hip subluxation or dislocation, and significant contractures
• Respiratory status: baseline function, use of noninvasive ventilation or cough assist, tracheostomy if present, and history of pneumonia or respiratory failure
• Nutrition and swallowing status, including gastrostomy feeding if applicable, given the rate of vomiting and gastroenteritis reported
• Mobility and handling notes: wheelchair or power chair, transfer method, positioning preferences, and equipment arriving with the patient
• Venous access notes, including any history of difficult sticks or an existing central line, since this is a monthly infusion over years
• Baseline CPK if available, so that a later elevation can be interpreted against a starting point
• For patients of reproductive potential, pregnancy status and a note that the reproductive findings in animal studies have been discussed
• The managing neuromuscular center or neurologist, and who is responsible for the motor function assessments and the ongoing SMN2 therapy
• For patients under 18, the caregiver or guardian who will attend appointments and the preferred contact for scheduling